期刊
NATURE BIOTECHNOLOGY
卷 39, 期 3, 页码 293-301出版社
NATURE PORTFOLIO
DOI: 10.1038/s41587-021-00843-5
关键词
-
资金
- MIT Laboratory for Financial Engineering
Academic institutions play a key role in the biotech industry through technology licensing and startup creation. A systematic study of technology licensing by MIT shows significant impact in the biopharmaceutical field, including MIT patents cited in the Orange Book, capital raised, patents granted, drug candidates discovered, and US drug approvals. This methodology may be helpful for other academic institutions to track outcomes of intellectual property in the therapeutics domain.
Academic institutions play a central role in the biotech industry through technology licensing and the creation of startups, but few data are available on their performance and the magnitude of their impact. Here we present a systematic study of technology licensing by one such institution, the Massachusetts Institute of Technology (MIT). Using data on the 76 therapeutics-focused life sciences companies formed through MIT's Technology Licensing Office from 1983 to 2017, we construct several measures of impact, including MIT patents cited in the Orange Book, capital raised, outcomes from mergers and acquisitions, patents granted to MIT intellectual property licensees, drug candidates discovered and US drug approvals-a key benchmark of innovation in the biopharmaceutical industry. As of December 2017, Orange Book listings for four approved small-molecule drugs cite MIT patents, but another 31 FDA-approved drugs (excluding candidates acquired after phase 3) had some involvement of MIT licensees. Fifty-five percent of the latter were either a new molecular entity or a new biological entity, and 55% were granted priority review, an indication that they address an unmet medical need. The methodology described here may be a useful framework for other academic institutions to track outcomes of intellectual property in the therapeutics domain.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据